Users of DRSP vs Users of LNG: Number of Participants With Venous Thromboembolism (VTE)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.00157 | 0.00107 | 0.0023 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.00162 | 0.0011 | 0.00239 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.0000479 | -0.000966 | 0.00085 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.97 | 0.561 | 1.68 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.97 | 0.56 | 1.68 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Users of DRSP than on Users of LNG | 20,900 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Users of DRSP | Women who use authorized oral contraceptives containing DRSP prescribed by their gynecologist | 26 | 16,534 | OG000 | ClinicalTrials.gov |
| Group 2 | Users of LNG | Women who use authorized oral contraceptives containing LNG prescribed by their gynecologist | 25 | 15,428 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | PRIMARY | ClinicalTrials.gov |
| Title | Number of Participants With Venous Thromboembolism (VTE) | ClinicalTrials.gov |
| Description | ClinicalTrials.gov | |
| Time frame | 1.5 to 5 years | ClinicalTrials.gov |
| Population | The primary analysis compares the users of DRSP and LNG. Its results are presented below. The comparison of users of DRSP and OCs containing other progestins was only conducted for exploratory reasons. This secondary analysis showed similar results and is described in more detail in the publication of study results, see citations. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | European Active Surveillance Study (EURAS) | ClinicalTrials.gov |
| NCT number | NCT00302848 | ClinicalTrials.gov |
| Phases | ClinicalTrials.gov | |
| Conditions | Contraception | ClinicalTrials.gov |
| Interventions | Drospirenone, Levonorgestrel, Other progestin containing oral contraceptive | ClinicalTrials.gov |
| Lead sponsor | Center for Epidemiology and Health Research, Germany | ClinicalTrials.gov |
| Results first posted | 2009-11-20 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT00302848?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.